If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Trulicity ® (dulaglutide) injection0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should other medications be administered with Trulicity® (dulaglutide)?
Consider reducing insulin/insulin secretagogue dose when initiating dulaglutide. Dulaglutide may reduce absorption of orally co-administered drugs.
Concomitant Use With an Insulin Secretagogue or With Insulin
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
- insulin secretagogues, such as sulfonylureas, or
Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs
Dulaglutide delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of dulaglutide.1
Because dulaglutide slows gastric emptying, it may reduce the extent and rate of absorption of orally co-administered medications. Monitor drug levels of oral medications with a narrow therapeutic index, like warfarin, when concomitantly administered with dulaglutide.1
In clinical pharmacology studies, dulaglutide 1.5 mg did not affect the absorption, to any clinically relevant degree, of the tested orally administered medications that included
- R-warfarin, and
There is limited experience with the use of concomitant medications in clinical trials with dulaglutide doses of 3 mg and 4.5 mg.1
Potential for Co-Administered Drugs to Influence the Pharmacokinetics of Dulaglutide
The co-administration of a single dose of 1.5 mg dulaglutide, with a steady-state dose of 100 mg sitagliptin, caused an increase in dulaglutide AUC and Cmax of approximately 38% and 27%. This was not considered to be clinically relevant, respectively.1
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530. https://doi.org/10.1155/2011/279530
3Smits MM, Tonneijck L, Muskiet MH, et al. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224-235. https://doi.org/10.1111/dom.12593
AUC = area under the curve
BG = blood glucose
Cmax = maximum serum concentration
GLP-1 RA = glucagon-like peptide-1 receptor agonist
Date of Last Review: September 10, 2020